Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life and low intersubject variability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback